Loading
A phase 3 trial testing HS-20093 in non-small-cell lung cancer, now recruiting.
ARTEMIS-008：HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer is a phase 3 interventional study registered as NCT06498479, led by Hansoh BioMedical R&D, and recruiting on the registry. Official title: ARTEMIS-008：A Multicenter, Randomised, Open-label, Phase 3 Study of HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer After Platinum-based First-line Chemotherapy. Planned enrolment is 460 participants (estimated). The study started in 2024-07-04 and primary completion is expected in 2026-09-30. No results have been posted on ClinicalTrials.gov.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares HS-20093, Hansoh Pharmaceutical.
Shares HS-20093, Hansoh Pharmaceutical.
Shares HS-20093, Hansoh Pharmaceutical.
Shares HS-20093, Hansoh Pharmaceutical.
Shares HS-20093, Hansoh Pharmaceutical, Non-small-cell lung cancer.
Shares HS-20093, Hansoh Pharmaceutical.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/